Tag Archives: treatment

9/11 Fund Now Includes Ovarian Cancer

A $4.3 billion fund to compensate and treat people exposed to potential toxins from 9/11 now includes many types of cancer, including ovarian. The inclusion of cancers in this fund … Continue reading 

Posted in News | Also tagged , , | Leave a comment

An Update on PARP Inhibitors

Development of PARP inhibitors, which appear to work best in women with BRCA mutations, has faced setbacks recently. An article reviews the data, good and bad, about PARP inhibitors. The … Continue reading 

Posted in News | Also tagged , , , , , | Leave a comment

Study Shows Some Benefit to Second Debulking Surgery Followed by HIPEC

A study of 56 patients in Italy who had ovarian cancer showed that women with recurrent ovarian cancer benefited from a second debulking surgery followed by HIPEC. HIPEC, or hyperthermic … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Decision Tool for women with BRCA Mutations Released

The Stanford Medicine Cancer Clinic has designed an online tool for women with a BRCA mutation. These genetic mutations increase a woman’s risk of developing breast and ovarian cancer. The … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Phase III Trial of Bevacizumab with Chemotherapy

A Phase III trial of bevacizumab (Avastin) with gemcitabine + carboplatin versus gemcitabine + carboplatin in women with ovarian cancer showed the bevacizumab arm to improve progression free survival (PFS). … Continue reading 

Posted in News | Also tagged , , , , , | Leave a comment

Olaparib shows improvement in PFS but not OS, Thus Far

Olaparib, a PARP inhibitor, showed an 3.6 month improvement in progression free survival (PFS) in women with platinum sensitive recurrent ovarian cancer. However, based on the interim analsis, there is … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Study Argues for Increased Use of PARP Inhibitors

A study from the Oregon Health & Science University suggests that women who have a recurrence of ovarian cancer would benefit from PARP inhibitors, now being tested in women with hereditary … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Chemotherapy Causes Changes in the Brain

According to MRI results, chemotherapy causes small changes to fibers that connect neurons in the brain. These are associated with a decline in cognitive function. Read an article about the study … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Race, Insurance Status, Influence Treatment of Ovarian Cancer

A study of more than 47,000 women with ovarian cancer found that uninsured and Medicaid patients were less likely to receive the standard of care. Additionally, women who were African … Continue reading 

Posted in News | Also tagged , , , , , , | Leave a comment

Avastin Shown to Slow Tumor Growth; Not Prolong Life

Two studies of the use of Avastin in ovarian cancer showed that the drug slowed tumor growth but did not improve overall survival. “While we are looking for that silver … Continue reading 

Posted in News | Also tagged , , , , , , | Leave a comment

PARP Inhibitor Olarparib Fails to Meet Trial Endpoints

AstraZeneca announced that it would not continue trials of olarparib in ovarian cancer due to the results of the Phase II trial. The company’s press release is available here

Posted in News | Also tagged , , , | Leave a comment

EU Approves Use of Avastin for Ovarian Cancer

The European Commission has approved the use of Avastin in women newly diagnosed with ovarian cancer. Read more on this topic here

Posted in News | Also tagged , , , | Leave a comment